RESUMO
Objective: School refusal (SR) is considered as a clinical form of emotionally based school absenteeism related to the experience of strong negative emotions when attending school. However, there are no psychometrically sound measures specifically designed to assess SR. The aim of the present research was to develop and validate a multidimensional self-report measure of SR: the SChool REfusal EvaluatioN Scale (SCREEN) for adolescents. Methods: Two studies were performed to develop this scale. Study 1 used content analysis on 42 semi-directed interviews to identify and organize the indicators of SR and to generate items. The item pool was then reviewed by experts to construct a pilot scale. Study 2 examined the psychometric properties of this pilot scale of the SCREEN in a community sample of 649 French adolescents (age: 10-16 years) and a clinical sample of 31 adolescents. Results: The initial SCREEN structure was identified via exploratory factor analysis, and the resultant model was validated using confirmatory factor analysis. In its final version (an 18-item, four-factor measurement model), the SCREEN reliably measures four interrelated aspects of SR. Data suggest good reliability and validity of scores on this SR measure. Results of the receiver operating characteristic (ROC) curve analysis indicated good accuracy of the SCREEN (sensitivity = .94 and specificity = .88). Conclusions: The SCREEN offers a new and valid measure to assess SR in research and clinical settings.
Assuntos
Absenteísmo , Emoções , Inquéritos e Questionários/normas , Adolescente , Criança , Análise Fatorial , Feminino , França , Humanos , Entrevistas como Assunto , Masculino , Psicometria , Reprodutibilidade dos Testes , AutorrelatoRESUMO
IMPORTANCE: Post-pandemic, it is essential to understand the epidemiology of pediatric acute respiratory tract infections (ARTIs). Our multi-facility study elucidates the outpatient epidemiology of pediatric ARTI using highly multiplexed PCR testing, providing critical insights into the evolving landscape of the etiological agents with a particular focus on the years following the emergence of SARS-CoV-2. Utilizing data from two different multiplex PCR panels, our research provides a comprehensive analysis of respiratory pathogen positivity from 2018 to 2023. Our findings indicate that over half of the annual test results identified at least one pathogen, primarily of viral origin. Intriguingly, despite the surge in testing during the COVID-19 pandemic, pathogen detection rates remain similar to the pre-pandemic era. These data hold significant implications for directing antimicrobial stewardship strategies, curbing unnecessary antibiotic use in pediatric respiratory diseases, and the value of multiplex PCR testing in the outpatient setting among pediatrics.
Assuntos
Pacientes Ambulatoriais , Infecções Respiratórias , Criança , Humanos , Reação em Cadeia da Polimerase Multiplex/métodos , Pandemias , Infecções Respiratórias/diagnóstico , Infecções Respiratórias/epidemiologia , Infecções Respiratórias/tratamento farmacológico , Antibacterianos/uso terapêuticoRESUMO
Dengue is a serious mosquito-transmitted disease caused by the dengue virus (DENV). Rapid and reliable diagnosis of DENV infection is urgently needed in dengue-endemic regions. We describe here the performance evaluation of the CE-marked VIDAS® dengue immunoassays developed for the automated detection of DENV NS1 antigen and anti-DENV IgM and IgG antibodies. A multicenter concordance study was conducted in 1296 patients from dengue-endemic regions in Asia, Latin America, and Africa. VIDAS® dengue results were compared to those of competitor enzyme-linked immunosorbent assays (ELISA). The VIDAS® dengue assays showed high precision (CV ≤ 10.7%) and limited cross-reactivity (≤15.4%) with other infections. VIDAS® DENGUE NS1 Ag showed high positive and negative percent agreement (92.8% PPA and 91.7% NPA) in acute patients within 0-5 days of symptom onset. VIDAS® Anti-DENGUE IgM and IgG showed a moderate-to-high concordance with ELISA (74.8% to 90.6%) in post-acute and recovery patients. PPA was further improved in combined VIDAS® NS1/IgM (96.4% in 0-5 days acute patients) and IgM/IgG (91.9% in post-acute patients) tests. Altogether, the VIDAS® dengue NS1, IgM, and IgG assays performed well, either alone or in combination, and should be suitable for the accurate diagnosis of DENV infection in dengue-endemic regions.